Gynavista
Letrozole (2.5mg)
Truvizole New 2.5mg Tablet is used to treat breast cancer in post-menopausal women, either alone or with other treatments, and to stop the tumor from spreading to other parts of the body.
Tablet
Truvizole New 2.5mg Tablet is an aromatase inhibitor that helps treat breast cancer in post-menopausal women. It works by decreasing the amount of estrogen produced in the body, which can slow down or stop the growth of some breast cancers that need estrogen to grow. It may be used alone or with other treatments, such as surgery or radiation.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Truvizole New 2.5mg Tablet may be taken with or without food but it is better to take it at a fixed time.
No common side effects listed.
Consuming alcohol with Truvizole New 2.5mg Tablet does not cause any harmful side effects.
Truvizole New 2.5mg Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Truvizole New 2.5mg Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Estradiol Ethinyl Estradiol Tibolone Estriol
Truvizole New 2.5mg Tablet is an aromatase inhibitor. It works by decreasing the amount of estrogen (natural female hormone) produced in the body. This decrease in estrogen can slow down or stop the growth of some breast cancers that need estrogen to grow.
You have been prescribed Truvizole New 2.5mg Tablet for the treatment of breast cancer. It can be taken with or without food. Do not drive or do anything requiring concentration until you know how Truvizole New 2.5mg Tablet affects you. It may cause increased sweating and hot flushes. Try to keep cool by wearing light and airy clothes. Your doctor may monitor your cholesterol level and bone mineral density (BMD) regularly as Truvizole New 2.5mg Tablet can alter their levels.
Truvizole New 2.5mg Tablet is an aromatase inhibitor, prescribed to treat estrogen-dependent breast cancer in women who no longer have periods due to menopause, surgery, or chemotherapy.
Truvizole New 2.5mg Tablet is an anti-estrogen drug that acts by blocking the enzyme aromatase, which produces estrogen in your body. Estrogen stimulates certain types of breast cancer growth. By reducing estrogen production, Truvizole New 2.5mg Tablet may prevent tumor growth.
If the breast tumor is in an advanced stage or has spread to other parts of the body, continue taking Truvizole New 2.5mg Tablet until the tumor shows progression. If given after tamoxifen (another anti-estrogen used for breast cancer) or surgery, it should be continued for 5 years or until the tumor comes back, whichever is first. It can also be administered as sequential treatment: 2 years of Truvizole New 2.5mg Tablet followed by 3 years of tamoxifen.
Yes, you can take irbesartan and Truvizole New 2.5mg Tablet together. However, be careful and monitor your blood pressure regularly as Truvizole New 2.5mg Tablet may increase it.
Although rare, Truvizole New 2.5mg Tablet can cause a cataract. If you experience blurred vision or eye irritation, consult your doctor immediately.
This could be due to hot flushes, which are a common side effect of Truvizole New 2.5mg Tablet. They occur due to the decrease in estrogen levels. The frequency of hot flushes reduces as your body adjusts to the treatment. In some cases, the flushes and sweats may persist during treatment and stop a few months after it ends. Consult your doctor if they are troublesome.
Serious side effects of Truvizole New 2.5mg Tablet, although rare, include stroke, angina, heart attack, blood clotting, cataract, osteoporosis, and severe skin reactions.
Truvizole New 2.5mg Tablet can cause thinning or wasting of your bones (osteoporosis), which is due to the decrease in estrogen levels in your body.
According to the Ministry of Health and Family Welfare, Truvizole New 2.5mg Tablet is restricted for use in inducing ovulation in anovulatory infertility.